Canaccord Genuity Maintains Hold on ANI Pharmaceuticals, Lowers Price Target to $90

Benzinga Newsdesk www.benzinga.com Negative 69.3%

Neg 69.3% Neu 0% Pos 0%

Canaccord Genuity analyst Gary Nachman maintains ANI Pharmaceuticals (NASDAQ:ANIP) with a Hold and lowers the price target from $91 to $90.